1. Craig AJ, von Felden J, Garcia-Lezana T, Sarcognato S, Villanueva A. Tumour evolution in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2020;17:139-52. doi: 10.1038/s41575-019-0229-4.
2. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209-49. doi: 10.3322/caac.21660.
3. Chen X, Zhang X, Zhang L, Gao Y, Wang C, Hong W, et al. Amphiphilic Janus nanoparticles for imaging-guided synergistic chemo-photothermal hepatocellular carcinoma therapy in the second near-infrared window. Nanoscale. 2021;13:3974-82. doi: 10.1039/d0nr09017d.
4. Zhang Z, He CZ, Qin YQ, Liao JJ, Huang ST, Mo S, et al. Exploring the mechanism of resistance to sorafenib in two hepatocellular carcinoma cell lines. Aging (Albany NY). 2020;12:24255-69. doi: 10.18632/aging.104195.
5. Jin X, Jiang ML, Wu ZH, Fan Y. Progress of Individualized Chemotherapy for Gastric Carcinoma Under the Guidance of Genetic Testing. Curr Med Chem. 2020;27:2322-34. doi: 10.2174/0929867326666190204123101.
6. Xia S, Pan Y, Liang Y, Xu J, Cai X. The microenvironmental and metabolic aspects of sorafenib resistance in hepatocellular carcinoma. EBioMedicine. 2020;51:102610. doi: 10.1016/j.ebiom.2019.102610.
7. Cao J, Wu L, Lei X, Shi K, Shi L. A signature of 13 autophagy‑related gene pairs predicts prognosis in hepatocellular carcinoma. Bioengineered. 2021;12:697-707. doi: 10.1080/21655979.2021.1880084.
8. Li Q, Ni Y, Zhang L, Jiang R, Xu J, Yang H, et al. HIF-1α-induced expression of m6A reader YTHDF1 drives hypoxia-induced autophagy and malignancy of hepatocellular carcinoma by promoting ATG2A and ATG14 translation. Signal Transduct Target Ther. 2021;6:76. doi: 10.1038/s41392-020-00453-8.
9. Zheng Y, Huang C, Lu L, Yu K, Zhao J, Chen M, et al. STOML2 potentiates metastasis of hepatocellular carcinoma by promoting PINK1-mediated mitophagy and regulates sensitivity to lenvatinib. J Hematol Oncol. 2021;14:16. doi: 10.1186/s13045-020-01029-3.
10. Okubo S, Ohta T, Fujita H, Shoyama Y, Uto T. Costunolide and dehydrocostuslactone from Saussurea lappa root inhibit autophagy in hepatocellular carcinoma cells. J Nat Med. 2021;75:240-5. doi: 10.1007/s11418-020-01462-1.
11. Kudo M. Scientific Rationale for Combined Immunotherapy with PD-1/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular Carcinoma. Cancers (Basel). 2020;12:1089. doi: 10.3390/cancers12051089.
12. Paver EC, Cooper WA, Colebatch AJ, Ferguson PM, Hill SK, Lum T, et al. Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation. Pathology. 2021;53:141-56. doi: 10.1016/j.pathol.2020.10.007.
13. Shigeta K, Datta M, Hato T, Kitahara S, Chen IX, Matsui A, et al. Dual Programmed Death Receptor-1 and Vascular Endothelial Growth Factor Receptor-2 Blockade Promotes Vascular Normalization and Enhances Antitumor Immune Responses in Hepatocellular Carcinoma. Hepatology. 2020;71:1247-61. doi: 10.1002/hep.30889.
14. Xu WP, Liu JP, Feng JF, Zhu CP, Yang Y, Zhou WP, et al. miR-541 potentiates the response of human hepatocellular carcinoma to sorafenib treatment by inhibiting autophagy. Gut. 2020;69:1309-21. doi: 10.1136/gutjnl-2019-318830.
15. Zhang YJ, Pan Q, Yu Y, Zhong XP. microRNA-519d Induces Autophagy and Apoptosis of Human Hepatocellular Carcinoma Cells Through Activation of the AMPK Signaling Pathway via Rab10. Cancer Manag Res. 2020;12:2589-602. doi: 10.2147/CMAR.S207548.
16. Wu L, Li H, Chen S, Wu X, Chen X, Wang F. Catalpol inhibits the proliferation, migration and metastasis of HCC cells by regulating miR-140-5p expression. Mol Med Rep. 2021;23:29. doi: 10.3892/mmr.2020.11667.
17. Flamini V, Jiang WG, Cui Y. Therapeutic Role of MiR-140-5p for the Treatment of Non-small Cell Lung Cancer. Anticancer Res. 2017;37:4319-27. doi: 10.21873/anticanres.11825.
18. Gao X, Jiang Y, Li Y. Inhibitory effect of miR-140-5p on doxorubicin resistance of hepatocellular carcinoma. Exp Ther Med. 2021;21:507. doi: 10.3892/etm.2021.9938.
19. Vijayanarasimha D, Nayanar SK, Vikram S, Patil VM, Babu S, Satheesan B. Clinico-pathological Study of Limb Salvage Surgery for Osteosarcoma: Experience in a Rural Cancer Center. Indian J Surg Oncol. 2017;8:136-41. doi: 10.1007/s13193-016-0547-8.
20. Cristino AS, Nourse J, West RA, Sabdia MB, Law SC, Gunawardana J, et al. EBV microRNA-BHRF1-2-5p targets the 3'UTR of immune checkpoint ligands PD-L1 and PD-L2. Blood. 2019;134:2261-70. doi: 10.1182/blood.2019000889.
21. Zhao L, Liu Y, Zhang J, Liu Y, Qi Q. LncRNA SNHG14/miR-5590-3p/ZEB1 positive feedback loop promoted diffuse large B cell lymphoma progression and immune evasion through regulating PD-1/PD-L1 checkpoint. Cell Death Dis. 2019;10:731. doi: 10.1038/s41419-019-1886-5.
22. Zhang J, Song Q, Wu M, Zheng W. The Emerging Roles of Exosomes in the Chemoresistance of Hepatocellular Carcinoma. Curr Med Chem. 2021;28:93-109. doi: 10.2174/0929867327666200130103206.
23. Ricke J, Klümpen HJ, Amthauer H, Bargellini I, Bartenstein P, de Toni EN, et al. Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma. J Hepatol. 2019;71:1164-74. doi: 10.1016/j.jhep.2019.08.006.
24. Oura K, Morishita A, Masaki T. Molecular and Functional Roles of MicroRNAs in the Progression of Hepatocellular Carcinoma-A Review. Int J Mol Sci. 2020;21:8362. doi: 10.3390/ijms21218362.
25. Liu Z, He F, OuYang S, Li Y, Ma F, Chang H, et al. miR-140-5p could suppress tumor proliferation and progression by targeting TGFBRI/SMAD2/3 and IGF-1R/AKT signaling pathways in Wilms' tumor. BMC Cancer. 2019;19:405. doi: 10.1186/s12885-019-5609-1.
26. Valihrach L, Androvic P, Kubista M. Circulating miRNA analysis for cancer diagnostics and therapy. Mol Aspects Med. 2020;72:100825. doi: 10.1016/j.mam.2019.10.002.
27. Jingjing W, Wenzheng G, Donghua W, Guangyu H, Aiping Z, Wenjuan W. Deubiquitination and stabilization of programmed cell death ligand 1 by ubiquitin-specific peptidase 9, X-linked in oral squamous cell carcinoma. Cancer Med. 2018;7:4004-11. doi: 10.1002/cam4.1675.
28. Iwatate Y, Hoshino I, Yokota H, Ishige F, Itami M, Mori Y, et al. Radiogenomics for predicting p53 status, PD-L1 expression, and prognosis with machine learning in pancreatic cancer. Br J Cancer. 2020;123:1253-61. doi: 10.1038/s41416-020-0997-1.
29. Poggio M, Hu T, Pai CC, Chu B, Belair CD, Chang A, et al. Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory. Cell. 2019;177:414-27. doi: 10.1016/j.cell.2019.02.016.
30. Zhang M, Wang N, Song P, Fu Y, Ren Y, Li Z, et al. LncRNA GATA3-AS1 facilitates tumour progression and immune escape in triple-negative breast cancer through destabilization of GATA3 but stabilization of PD-L1. Cell Prolif. 2020;53:e12855. doi: 10.1111/cpr.12855.
31. Lou G, Chen L, Xia C, Wang W, Qi J, Li A, et al. MiR-199a-modified exosomes from adipose tissue-derived mesenchymal stem cells improve hepatocellular carcinoma chemosensitivity through mTOR pathway. J Exp Clin Cancer Res. 2020;39:4. doi: 10.1186/s13046-019-1512-5.
32. Abd-Elbaset M, Mansour AM, Ahmed OM, Abo-Youssef AM. The potential chemotherapeutic effect of β-ionone and/or sorafenib against hepatocellular carcinoma via its antioxidant effect, PPAR-γ, FOXO-1, Ki-67, Bax, and Bcl-2 signaling pathways. Naunyn Schmiedebergs Arch Pharmacol. 2020;393:1611-24. doi: 10.1007/s00210-020-01863-9.
33. Morrissey SM, Yan J. Exosomal PD-L1: Roles in Tumor Progression and Immunotherapy. Trends Cancer. 2020;6:550-8. doi: 10.1016/j.trecan.2020.03.002.
34. Hong W, Xue M, Jiang J, Zhang Y, Gao X. Circular RNA circ-CPA4/ let-7 miRNA/PD-L1 axis regulates cell growth, stemness, drug resistance and immune evasion in non-small cell lung cancer (NSCLC). J Exp Clin Cancer Res. 2020;39:149. doi: 10.1186/s13046-020-01648-1.